![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Harvard Bioscience Inc is a US-based developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and researc... Harvard Bioscience Inc is a US-based developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America and Europe, it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The majority of its revenue comes from the United States. Show more
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology PR Newswire SAN JOSE, Calif., Aug. 1, 2024 BridGene Eligible to...
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’...
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights...
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centersCollaboration enables rapid...
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -5.81039755352 | 3.27 | 3.4353 | 3.04 | 113125 | 3.26889595 | CS |
4 | 0.31 | 11.1913357401 | 2.77 | 3.6 | 2.7 | 128802 | 3.17779711 | CS |
12 | -0.62 | -16.7567567568 | 3.7 | 3.85 | 2.7 | 157895 | 3.02920534 | CS |
26 | -1.33 | -30.1587301587 | 4.41 | 4.93 | 2.7 | 122976 | 3.51791696 | CS |
52 | -1.56 | -33.6206896552 | 4.64 | 5.56 | 2.7 | 112380 | 3.95885873 | CS |
156 | -4.91 | -61.4518147685 | 7.99 | 8.75 | 1.98 | 161789 | 4.8015453 | CS |
260 | 0.6 | 24.1935483871 | 2.48 | 8.75 | 1.39 | 167037 | 4.61287017 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions